- Home
- WPM vs TAK Comparison
WPM vs TAK Comparison
Compare WPM & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WPM | TAK |
|---|---|---|
| Founded | 2004 | 1781 |
| Country | Canada | Japan |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3B | 43.3B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | WPM | TAK |
|---|---|---|
| Price | $126.00 | $15.81 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $132.50 | N/A |
| AVG Volume (30 Days) | 1.7M | ★ 2.4M |
| Earning Date | 11-06-2025 | 01-29-2026 |
| Dividend Yield | 0.55% | ★ 3.36% |
| EPS Growth | ★ 64.06 | N/A |
| EPS | ★ 2.20 | 0.14 |
| Revenue | $1,830,402,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $64.33 | N/A |
| Revenue Next Year | $22.83 | $0.47 |
| P/E Ratio | ★ $54.91 | $112.61 |
| Revenue Growth | ★ 50.33 | N/A |
| 52 Week Low | $55.51 | $12.80 |
| 52 Week High | $125.62 | $15.78 |
Technical Indicators
Market Signals| Indicator | WPM | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 67.03 | 75.92 |
| Support Level | $114.51 | $15.48 |
| Resistance Level | $124.30 | $15.78 |
| Average True Range (ATR) | 3.67 | 0.18 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 99.16 | 88.64 |
Price Performance
Historical ComparisonAbout WPM Wheaton Precious Metals Corp (Canada)
Wheaton Precious Metals Corp is a precious metal streaming company. Its reportable segment includes: Gold, Silver, Palladium, Platinum, Cobalt, and Other. It generates its revenue from the sale of precious metals (gold, silver and palladium) and cobalt.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.